B/BE/97/VW9
| Company/Institution | Merial |
| Parental organism | Canarypoxvirus (ALVAC clone) |
| Transgene(s) | env and gag genes of the type A virus of feline leukemia (FELV) |
| Treated organism | cats |
| Title of the project | Development of a live vaccine against feline leukemia. Experiment outside containment (clinical trial) for the study of the safety of a sucutaneous administration of a recombinant canarypoxvirus expressing FELV genes. |
| Treatment indication | vaccination against feline leukemia virus (FELV) |
| Administration route(s) | subcutaneous |
| Total number of subjects foreseen | 400 |
| Foreseen duration of release | 6 months |
| Effective year(s) of release | not communicated |
| Current status | Authorization procedure completed. The notifier was granted authorization from the Federal Minister to perform the trial. Trial completed |
| Locations | Merksem, Heverlee, Mechelen, Deurne, Izegem, Haine St Pierre, Ternat, Overijse, Liège |
| Number of sites | 9 |
| Monitoring | |
| Type of procedure | Classical procedure - Art. 9§1 of Royal Decree of 18 December 1998 |
| Notes | |
| Other |
Information for the public
Information related to the decision procedure
-
B/BE/97/VW9 - Advice Biosafety Advisory Council a.i.
6 April 1997: The Biosafety Advisory Council a.i. issues a positive advice (with conditions) for this trial.
